1. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385-92.
2. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999;175:576-80.
4. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Human Psychopharmacology: Clinical and Experimental. 2008;23(S1):S27-S41.
5. Pirmohamed M, Park K. Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development. CNS Drugs. 1997;7(2):139-58.
6. Spencer BW, Prainsack B, Rujescu D, Giegling I, Collier DA, Gaughran F, et al. Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for clozapine. Pharmacogenomics. 2013;14(15):1907-14.
7. Sriretnakumar V, Huang E, Müller DJ. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update. Expert Opin Drug Metab Toxicol. 2015:1-23.
8. Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E, et al. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular Psychiatry. 2017;23:162.
9. Legge SE, Walters JTR. Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective. Pharmacogenomics. 2019;20(4):279-90.
10. Verbelen M, Collier DA, Cohen D, MacCabe JH, Lewis CM. Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis. Pharmacogenomics J. 2015;15(5):461-6.
11. Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res. 2012;140(1-3):204-13.
12. von Vietinghoff S, Ley K. Homeostatic Regulation of Blood Neutrophil Counts. The Journal of Immunology. 2008;181(8):5183-8.
13. Souto Filho JTD, Portugal RD, Nucci M. Effect of circadian variation on neutrophil mobilization to the peripheral blood in benign constitutional neutropenia. Experimental Hematology. 2019;69:22-6.
14. Ahokas A, Elonen E. Circadian rhythm of white blood cells during clozapine treatment. Psychopharmacology (Berl). 1999;144(3):301-2.
15. McKee JR, Wall T, Owensby J. Impact of complete blood count sampling time change on white blood cell and absolute neutrophil count values in clozapine recipients. Clin Schizophr Relat Psychoses. 2011;5(1):26-32.
16. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146(7):486-92.
17. McCarthy DA, Dale MM. The Leucocytosis of Exercise. Sports Medicine. 1988;6(6):333-63.
18. Phillips R, Hancock B, Graham J, Bromham N, Jin H, Berendse S. Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance. Bmj. 2012;345:e5368.
19. Dale DC. How I diagnose and treat neutropenia. Current opinion in hematology. 2016;23(1):1-4.
20. Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Seminars in hematology. 2013;50(3):198-206.
21. Jakobsen MI, Larsen JR, Svensson CK, Johansen SS, Linnet K, Nielsen J, et al. The significance of sampling time in therapeutic drug monitoring of clozapine. Acta Psychiatr Scand. 2017;135(2):159-69.
23. Atallah-Yunes SA, Ready A, Newburger PE. Benign ethnic neutropenia. Blood Reviews. 2019;37:100586.
24. Reich D, Nalls MA, Kao WHL, Akylbekova EL, Tandon A, Patterson N, et al. Reduced Neutrophil Count in People of African Descent Is Due To a Regulatory Variant in the Duffy Antigen Receptor for Chemokines Gene. PLOS Genetics. 2009;5(1):e1000360.
25. Legge SE, Pardinas AF, Helthuis M, Jansen JA, Jollie K, Knapper S, et al. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Mol Psychiatry. 2019;24(3):328-37.
27. Eri Kuno, Ph.D. , and, Aileen B. Rothbard, Sc.D. Racial Disparities in Antipsychotic Prescription Patterns for Patients With Schizophrenia. American Journal of Psychiatry. 2002;159(4):567-72.
28. Whiskey E, Olofinjana O, Taylor D. The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study. J Psychopharmacol. 2011;25(6):842-5.
29. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry. 2006;188:255-63.
30. Prokopez CR, Armesto AR, Gil Aguer MF, Balda MV, Papale RM, Bignone IM, et al. Clozapine Rechallenge After Neutropenia or Leucopenia. J Clin Psychopharmacol. 2016;36(4):377-80.
31. Manu P, Lapitskaya Y, Shaikh A, Nielsen J. Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases. Am J Ther. 2018;25(2):e218-e23.
32. Focosi D, Azzarà A, Kast RE, Carulli G, Petrini M. Lithium and hematology: established and proposed uses. J Leukoc Biol. 2009;85(1):20-8.
33. Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res. 2012;134(2-3):180-6.
34. Boazak M, Goldsmith DR, Cotes RO. Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky. Prim Care Companion CNS Disord. 2018;20(6).
35. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry. 2006;67(5):756-60.
36. Small JG, Klapper MH, Malloy FW, Steadman TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol. 2003;23(3):223-8.
37. Gerson SL, Lieberman JA, Friedenberg WR, Lee D, Marx JJ, Jr., Meltzer H. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet. 1991;338(8761):262-3.
38. Valevski A, Modai I, Lahav M, Weizman A. Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol. 1993;8(1):63-5.
39. Cavanagh J, University of Glasgow Department of Psychological Medicine AC, Gartnavel Royal Hospital, Glasgow, UK, Smyth R, Royal Edinburgh Hospital MP, Edinburg, UK, Goodwin GM, University of Glasgow Department of Psychological Medicine AC, Gartnavel Royal Hospital, Glasgow, UK, et al. Relapse into mania or depression following lithium discontinuation: a 7‐year follow‐up. Acta Psychiatrica Scandinavica. 2004;109(2):91-5.
40. Wickramanayake PD, Scheid C, Josting A, Katay I, Schulz A, Diehl V. Use of granulocyte colony-stimulating factor (filgrastim) in the treatment of non-cytotoxic drug-induced agranulocytosis. Eur J Med Res. 1995;1(3):153-6.
41. Pamphilon D, Nacheva E, Navarrete C, Madrigal A, Goldman J. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion. 2008;48(7):1495-501.
42. Cornes P, Krendyukov A. The evolution of value with filgrastim in oncology. Future Oncol. 2019;15(13):1525-33.
43. Blier P, Slater S, Measham T, Koch M, Wiviott G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol. 1998;13(3):137-40.
44. Weide R, Koppler H, Heymanns J, Pfluger KH, Havemann K. Successful treatment of clozapine induced agranulocytosis with granulocyte-colony stimulating factor (G-CSF). Br J Haematol. 1992;80(4):557-9.
45. Sperner-Unterweger B, Czeipek I, Gaggl S, Geissler D, Spiel G, Fleischhacker WW. Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine. Br J Psychiatry. 1998;172:82-4.
46. Spencer BW, Williams HR, Gee SH, Whiskey E, Rodrigues JP, Mijovic A, et al. Granulocyte Colony Stimulating Factor (G-CSF) can allow treatment with clozapine in a patient with severe Benign Ethnic Neutropaenia (BEN): a case report. Journal of Psychopharmacology. 2012;26(9):1280-2.
47. Pasquale D, Newton M, Goss JB, Simor G, Lesieur S. Granulocyte colony-stimulating factor treatment of clozapine-induced agranulocytosis. Am J Psychiatry. 1996;153(11):1503-4.
48. Nielsen H. Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis. J Intern Med. 1993;234(5):529-31.
49. Majczenko TG, Stewart JT. Failure of filgrastim to prevent severe clozapine-induced agranulocytosis. South Med J. 2008;101(6):639-40.
50. Khan AA, Harvey J, Sengupta S. Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia. Ther Adv Psychopharmacol. 2013;3(5):266-71.
51. Joffe G, Eskelinen S, Sailas E. Add-on filgrastim during clozapine rechallenge in patients with a history of clozapine-related granulocytopenia/agranulocytosis. Am J Psychiatry. 2009;166(2):236.
52. Heinz P, Muller H, Bauer M. [Treatment of clozapine-induced agranulocytosis with granulocyte colony-stimulating factor G-CSF]. Psychiatr Prax. 1994;21(2):81.
53. Gullion G, Yeh HS. Treatment of clozapine-induced agranulocytosis with recombinant granulocyte colony-stimulating factor. J Clin Psychiatry. 1994;55(9):401-5.
54. Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry. 1994;55 Suppl B:139-42.
55. Gerson SL, Gullion G, Yeh HS, Masor C. Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis. Lancet. 1992;340(8827):1097.
56. Meyer N, Gee S, Whiskey E, Taylor D, Mijovic A, Gaughran F, et al. Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J Clin Psychiatry. 2015;76(11):e1410-6.
57. Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, et al. The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review. J Clin Psychopharmacol. 2017;37(5):600-4.
58. Lally J, Malik S, Whiskey E, Taylor DM, Gaughran FP, Krivoy A, et al. Clozapine-Associated Agranulocytosis Treatment With Granulocyte Colony-Stimulating Factor/Granulocyte-Macrophage Colony-Stimulating Factor: A Systematic Review. J Clin Psychopharmacol. 2017;37(4):441-6.
59. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz M, et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013;98(8):1282-90.
60. Platzbecker U, Prange-Krex G, Bornhauser M, Koch R, Soucek S, Aikele P, et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion. 2001;41(2):184-9.
61. DiMeglio LA, Bolyard AA, Marrero TM, Alter BP, Bonilla MA, Boxer LA, et al. The Risk of Low Bone Mineral Density with Long-Term G-CSF Therapy for Severe Chronic Neutropenia. Blood. 2010;116(21):1484-.
62. Shaw BE, Confer DL, Hwang W, Pulsipher MA. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplantation. 2015;50(3):334.
63. Honer WG, Jones AA, Thornton AE, Barr AM, Procyshyn RM, Vila-Rodriguez F. Response trajectories to clozapine in a secondary analysis of pivotal trials support using treatment response to subtype schizophrenia. Can J Psychiatry. 2015;60(3 Suppl 2):S19-25.
64. Suzuki T, Remington G, Arenovich T, Uchida H, Agid O, Graff-Guerrero A, et al. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. Br J Psychiatry. 2011;199(4):275-80.
65. Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003;42(7):607-18.
66. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005;162(5):939-46.
67. Department of Health. Mental Health Act 1983: Code of Practice. London: TSO; 2015.
68. Detzer D. Donnybrook: The Battle of Bull Run, 1861: Harcourt; 2005.
69. Dalal B, Larkin E, Leese M, Taylor PJ. Clozapine treatment of long-standing schizophrenia and serious violence: a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital. Criminal Behav Ment Health. 1999;9:168-78.
70. Swinton M, Haddock A. Clozapine in Special Hospital: a retrospective case-control study. The Journal of Forensic Psychiatry. 2000;11(3):587-96.
71. Ahalt C, Williams B. Reforming Solitary-Confinement Policy — Heeding a Presidential Call to Action. New England Journal of Medicine. 2016;374(18):1704-6.
to the Government of the United Kingdom
on the visit to the United Kingdom
carried out by the European Committee
for the Prevention of Torture and Inhuman
or Degrading Treatment or Punishment (CPT)
from 30 March to 12 April 2016. Strasbourg: Council of Europe; 2017.
73. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United States. New England Journal of Medicine. 1993;329(3):162-7.
74. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: A situation report up to August 1976. European Journal of Clinical Pharmacology. 1977;11(3):199-201.
75. Sultan RS, Olfson M, Correll CU, Duncan EJ. Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring. The Journal of clinical psychiatry. 2017;78(8):e933-e9.
76. Nielsen J, Young C, Ifteni P, Kishimoto T, Xiang YT, Schulte PF, et al. Worldwide Differences in Regulations of Clozapine Use. CNS Drugs. 2016;30(2):149-61.
77. Bastiampillai T, Gupta A, Chan SK, Allison S. Changes for clozapine monitoring in the United States. Mol Psychiatry. 2016;21(7):858-60.
78. Whiskey E, Dzahini O, Ramsay R, O'Flynn D, Mijovic A, Gaughran F, et al. Need to bleed? Clozapine haematological monitoring approaches a time for change. Int Clin Psychopharmacol. 2019;34(5):264-8.
79. Brown D, Larkin F, Sengupta S, Romero-Ureclay JL, Ross CC, Gupta N, et al. Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS Spectr. 2014;19(5):391-402.
80. Besag FM, Ng GY, Pool F. Successful re-introduction of lamotrigine after initial rash. Seizure. 2000;9(4):282-6.
81. Aiken CB, Orr C. Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry (Edgmont). 2010;7(5):27-32.
82. Eames P. Adverse reactions to carbamazepine managed by desensitisation. Lancet. 1. England1989. p. 509-10.